PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 12, 2015, Pages 1794-1800

  Giesel, Frederik L ^a,d   Fiedler, H ^a   Stefanova, M ^a   Sterzing, F ^b   Rius, M ^c,d   Kopka, K ^d   Moltz, J H ^d   Afshar Oromieh, A ^a   Choyke, P L ^e   Haberkorn, U ^a,d   Kratochwil, C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JOINT RESEARCH CENTRE   (Italy)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

68Ga PSMA 11 PET CT; Lymph node evaluation; Lymph node metastasis; Recurrent prostate cancer

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN 11 GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; EDETIC ACID; GLU-NH-CO-NH-LYS-(AHX)-((68)GA(HBED-CC)); OLIGOPEPTIDE;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONE BEAM COMPUTED TOMOGRAPHY; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; THREE DIMENSIONAL IMAGING; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOGRAPHY; RECURRENT DISEASE;

AGED; EDETIC ACID; HUMANS; IMAGING, THREE-DIMENSIONAL; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84942909663     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3106-6     Document Type: Article

References (26)

1. Kwon O, Kim KB, Lee YI, Byun SS, Kim JS, Lee SE, et al. Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes. PLoS One. 2014;9(7), e103574. doi:10.1371/journal.pone.0103574.2.
2. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.
3. Hövels AM, Heesakkersb RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387–95. doi:10.1016/j.crad.2007.05.0224.
4. Engeler CE, Wasserman NF, Zhang G. Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives. Urology. 1992;40:346–50.
5. Flanigan RC, McKay TC, Olson M, Shankey TV, Pyle J, Waters WB. Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology. 1996;48:428–32.
6. Hilton S, Herr HW, Teitcher JB, Begg CB, Castellino RA. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol. 1997;169:521–5.
7. Thoeny HC, Froehlich JM, Triantafulloy M, Huesler J, Bains LJ, Vermathen P, et al. Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. Radiology. 2014;273(1):125–35. doi:10.1148/radiol.14132921.
8. Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging. 2013;40:819–23. doi:10.1007/s00259-013-2374-2.
9. Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. J Nucl Med. 2004;45:1509–18.
10. Tempany CM, Zou KH, Silverman SG, Brown DL, Ab K, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities – report from the Radiological Diagnostic Oncology Group. Radiology. 2000;215:761–7.
11. Moltz JM, Bornemann L, Kuhnigk JM, Dicken V, Peitgen E, Meier S, et al. Advanced segmentation techniques for lung nodules, liver metastases, and enlarged lymph nodes in CT scans. IEEE J Sel Topics Signal Process. 2009;3:122–34.
12. McMahon CJ, Rofsky NM, Pedrosa I. Lymphatic metastases from pelvic tumors: anatomic classification, characterization and staging. Radiology. 2010;254:31–46. doi:10.1148/radiol.2541090361.
13. Maleike D, Fabel M, Tetzlaff R, von Tengg-Kobligk H, Heimann T, Meinzer HP, et al. Lymph node segmentation on CT images by a shape model guided deformable surface method. Proc SPIE. 2008;6914:69141S. doi:10.1117/12.770352
14. Wright GL, Mayer Grob B, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326–34.
15. Sterzing F, Fiedler H, Stefanova M, Afshar-Oromieh A, Kratochwil C, et al. Impact of 68Ga-PSMA PET/CT in staging of prostate cancer patient prior to radiation therapy. Int J Radiat Oncol Biol Phys. 2014;90(1):S449. doi:10.1016/j.ijrobp.2014.05.1407.
16. Heesakkers RA, Hovels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 2008;9:850–6. doi:10.1016/S1470-2045(08)70203-1.
17. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54:392–401. doi:10.1016/j.eururo.2008.04.030.
18. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. doi:10.1007/s00259-013-2386-y.
19. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. doi:10.1007/s00259-013-2525-5.
20. Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of 18F-fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol. 2006;1768(5):2014–8.
21. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(2):253–63.
22. Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015. doi:10.1007/s11307-015-0850-8
23. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108(23):9578–82. doi:10.1073/pnas.1106383108.
24. Liu T, Wu LY, Fulton MD, Johnson JM, Berkman C. Prolonged androgen deprivation leads to down regulation of androgen receptor and prostate specific membrane antigen in prostate cancer cells. Int J Oncol. 2012;41(6):2087–92. doi:10.3892/ijo.2012.1649.
25. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209. doi:10.1007/s00259-014-2949-6.
26. Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy R, Deroose CM, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol. 2011;60:125–30. doi:10.1016/j.eururo.2011.01.015.